ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Clin Exp Pathol 2016, Vol 6(5): 296
  • DOI: 10.4172/2161-0681.1000296

A Fatal Case of Cefazolin-Induced Immune Hemolytic Anemia in Iran

Moghaddam M1*, Razzaghi F2, Sheibani H1 and Pourfathollah AA3
1Immunohematology Department, Blood Transfusion Center, High Institute for Research Centre and Education in Transfusion Medicine, Tehran, Iran
2Reproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran
3Faculty of Medical Sciences, Tarbiat Modares University and Blood Transfusion Research Centre, High Institute for Research Centre and Education in Transfusion Medicine, Tehran, Iran
*Corresponding Author : Moghaddam M, Immunohematology Department, Blood Transfusion Centre, High Institute for Research Centre and Education in Transfusion Medicine, Tehran, Iran, Tel: +98 2188601606, Fax: +982188623218, Email: m.moghaddam@ibto.ir

Received Date: Oct 10, 2016 / Accepted Date: Oct 20, 2016 / Published Date: Oct 24, 2016

Abstract

Introduction: Drug-induced immune hemolytic anemia (DIIHA) is known as an unpredictable and in some cases serious complication occurring upon pharmacotherapy. Cefazolin, as a first generation cephalosporin used against gram-negative bacteria, has rarely been reported to cause hemolytic anemia. Here, we report the first fatal case of hemolytic anemia associated with cefazolin treatment. Materials and methods: A 24-year-old woman undergoing operative hysteroscopy for resection of the uterine septum developed hemolytic anemia upon receiving cefazolin immediately before and after the operation. A few hours after surgery, clinical signs of disseminated intravascular coagulation (DIC) appeared. Despite all supportive medical measures that were taken, the patient died of multiple organ failure about 24 hours after admission to ICU. The patient had no history of transfusion or allergies to any types of drugs including antibiotics. Direct anti-globulin test (DAT) was conducted, and the presence of antibody and complement on patient’s RBCs was investigated. In addition, the reaction between patient’s RBC eluate and cefazolin-coated control RBCs was explored. Results: DAT was strongly positive (4+); in addition, the presence of IgG4 and C3d on the patient’s RBCs was shown. Moreover, the eluate from patient’s RBCs reacted (3+) with RBCs pre-coated with cefazolin. Discussion: The results confirmed the presence of cefazolin-dependent antibodies. This case reveals the importance of taking precaution before using cefazolin even in cases where there is no previous evidence of drug sensitization.

Keywords: Cefazolin; Direct anti-globulin test; Disseminated intravascular coagulation; Immune-mediated hemolytic anemia

Citation: Moghaddam M, Razzaghi F, Sheibani H, Pourfathollah AA (2016) A Fatal Case of Cefazolin-Induced Immune Hemolytic Anemia in Iran. J Clin Exp Pathol 6:296. Doi: 10.4172/2161-0681.1000296

Copyright: © 2016 Moghaddam M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top